Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel Free ELTX Stock Alerts

Elicio Therapeutics (ELTX) Competitors

Elicio Therapeutics logo
$3.09 -0.06 (-1.90%)
Closing price 04:00 PM Eastern
Extended Trading
$3.17 +0.08 (+2.59%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ELTX vs. ACIU, CAPR, TARA, CHRS, and CGEN

Should you buy Elicio Therapeutics stock or one of its competitors? Elicio Therapeutics's main competitors and comparable companies include AC Immune (ACIU), Capricor Therapeutics (CAPR), Protara Therapeutics (TARA), Coherus Oncology (CHRS), and Compugen (CGEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Elicio Therapeutics compare to AC Immune?

AC Immune (NASDAQ:ACIU) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Elicio Therapeutics has lower revenue, but higher earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AC Immune$4.31M58.80-$85.03M-$0.54N/A
Elicio TherapeuticsN/AN/A-$39.57M-$2.40N/A

Elicio Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. AC Immune's return on equity of -100.17% beat Elicio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AC Immune-245.32% -100.17% -28.36%
Elicio Therapeutics N/A -2,827.47%-147.75%

In the previous week, AC Immune had 3 more articles in the media than Elicio Therapeutics. MarketBeat recorded 9 mentions for AC Immune and 6 mentions for Elicio Therapeutics. AC Immune's average media sentiment score of 1.33 beat Elicio Therapeutics' score of 0.70 indicating that AC Immune is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AC Immune
5 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Elicio Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

AC Immune currently has a consensus target price of $7.50, suggesting a potential upside of 201.20%. Elicio Therapeutics has a consensus target price of $19.75, suggesting a potential upside of 539.16%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Elicio Therapeutics is more favorable than AC Immune.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AC Immune
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Elicio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

AC Immune has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

51.4% of AC Immune shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 4.6% of AC Immune shares are held by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

AC Immune beats Elicio Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Elicio Therapeutics compare to Capricor Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Elicio Therapeutics presently has a consensus price target of $19.75, indicating a potential upside of 539.16%. Capricor Therapeutics has a consensus price target of $29.15, indicating a potential upside of 338.35%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Elicio Therapeutics is more favorable than Capricor Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elicio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Capricor Therapeutics
1 Sell rating(s)
9 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Elicio Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

Capricor Therapeutics' return on equity of -58.09% beat Elicio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Elicio TherapeuticsN/A -2,827.47% -147.75%
Capricor Therapeutics N/A -58.09%-48.01%

In the previous week, Capricor Therapeutics had 54 more articles in the media than Elicio Therapeutics. MarketBeat recorded 60 mentions for Capricor Therapeutics and 6 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 0.70 beat Capricor Therapeutics' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Elicio Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Capricor Therapeutics
3 Very Positive mention(s)
8 Positive mention(s)
43 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral

Elicio Therapeutics has higher earnings, but lower revenue than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elicio TherapeuticsN/AN/A-$39.57M-$2.40N/A
Capricor Therapeutics$22.27M17.29-$105.04M-$2.32N/A

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Elicio Therapeutics beats Capricor Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Elicio Therapeutics compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by insiders. Comparatively, 50.9% of Elicio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Protara Therapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protara TherapeuticsN/AN/A-$57.44M-$1.34N/A
Elicio TherapeuticsN/AN/A-$39.57M-$2.40N/A

Protara Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

Protara Therapeutics' return on equity of -41.72% beat Elicio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Protara TherapeuticsN/A -41.72% -38.78%
Elicio Therapeutics N/A -2,827.47%-147.75%

In the previous week, Protara Therapeutics had 9 more articles in the media than Elicio Therapeutics. MarketBeat recorded 15 mentions for Protara Therapeutics and 6 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 0.70 beat Protara Therapeutics' score of 0.44 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protara Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Elicio Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Protara Therapeutics presently has a consensus target price of $26.25, indicating a potential upside of 561.21%. Elicio Therapeutics has a consensus target price of $19.75, indicating a potential upside of 539.16%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Protara Therapeutics is more favorable than Elicio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protara Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
Elicio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Protara Therapeutics beats Elicio Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Elicio Therapeutics compare to Coherus Oncology?

Elicio Therapeutics (NASDAQ:ELTX) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

Coherus Oncology has higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elicio TherapeuticsN/AN/A-$39.57M-$2.40N/A
Coherus Oncology$42.17M4.40$168.02M-$1.03N/A

Elicio Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by insiders. Comparatively, 7.2% of Coherus Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Elicio Therapeutics had 4 more articles in the media than Coherus Oncology. MarketBeat recorded 6 mentions for Elicio Therapeutics and 2 mentions for Coherus Oncology. Elicio Therapeutics' average media sentiment score of 0.70 beat Coherus Oncology's score of 0.63 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Elicio Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Coherus Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Elicio Therapeutics currently has a consensus target price of $19.75, suggesting a potential upside of 539.16%. Coherus Oncology has a consensus target price of $8.67, suggesting a potential upside of 622.22%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Elicio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elicio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Coherus Oncology
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Elicio Therapeutics has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Coherus Oncology's return on equity of -222.75% beat Elicio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Elicio TherapeuticsN/A -2,827.47% -147.75%
Coherus Oncology -259.41%-222.75%-52.11%

Summary

Coherus Oncology beats Elicio Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Elicio Therapeutics compare to Compugen?

Compugen (NASDAQ:CGEN) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Compugen presently has a consensus target price of $5.00, indicating a potential upside of 107.47%. Elicio Therapeutics has a consensus target price of $19.75, indicating a potential upside of 539.16%. Given Elicio Therapeutics' higher probable upside, analysts plainly believe Elicio Therapeutics is more favorable than Compugen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compugen
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
Elicio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Compugen has higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compugen$72.76M3.13$35.34M$0.386.34
Elicio TherapeuticsN/AN/A-$39.57M-$2.40N/A

In the previous week, Elicio Therapeutics had 2 more articles in the media than Compugen. MarketBeat recorded 6 mentions for Elicio Therapeutics and 4 mentions for Compugen. Compugen's average media sentiment score of 1.11 beat Elicio Therapeutics' score of 0.70 indicating that Compugen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Compugen
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Elicio Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Compugen has a net margin of 47.56% compared to Elicio Therapeutics' net margin of 0.00%. Compugen's return on equity of 42.57% beat Elicio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Compugen47.56% 42.57% 26.13%
Elicio Therapeutics N/A -2,827.47%-147.75%

Compugen has a beta of 2.77, indicating that its share price is 177% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

12.2% of Compugen shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Compugen beats Elicio Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Elicio Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELTX vs. The Competition

Export
MetricElicio TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$60.12M$3.74B$7.06B$13.10B
Dividend YieldN/A3.69%2.57%10.45%
P/E Ratio-1.426.29211.0921.74
Price / SalesN/A1,295.89602.9892.99
Price / CashN/A102.8870.4850.90
Price / Book34.3316.7812.916.24
Net Income-$39.57M-$13.32M$3.45B$347.60M
7 Day Performance-3.13%1.74%1.12%1.07%
1 Month Performance-0.64%1.60%1.79%1.03%
1 Year Performance-67.98%56.43%67.69%20.77%

Elicio Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELTX
Elicio Therapeutics
3.1248 of 5 stars		$3.09
-1.9%		$19.75
+539.2%		-66.5%$60.12MN/AN/AN/A
ACIU
AC Immune
2.7084 of 5 stars		$2.32
+1.3%		$7.50
+223.3%		+16.8%$233.06M$4.31MN/A140
CAPR
Capricor Therapeutics
2.9019 of 5 stars		$4.18
+6.4%		$29.15
+597.4%		-49.3%$227.59M$22.27MN/A101
TARA
Protara Therapeutics
2.6331 of 5 stars		$4.10
+2.5%		$26.25
+540.2%		+20.9%$224.82MN/AN/A30
CHRS
Coherus Oncology
1.6764 of 5 stars		$1.27
-12.8%		$8.67
+585.1%		+14.1%$223.66M$50.94MN/A330

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ELTX) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel